Key Takeaways for the Management of PP

EP: 1.Overview of PP

EP: 2.The Role of Physician Assistants in PP Management

EP: 3.Factors to Consider when Treating PP

EP: 4.Impact of PP Comorbidities

EP: 5.Treatment Options for Pregnant People With PP

EP: 6.Caring for Pediatric Patients With PP

EP: 7.PP Treatment Selection: Best Practices

EP: 8.Drug Class Considerations for Patients With PP

EP: 9.PP Treatment Efficacy

EP: 10.Topical Therapy Options for PP

EP: 11.Plaque Psoriasis Treatment Selection Considerations

EP: 12.Aryl Hydrocarbon Receptor Treatments for PP

EP: 13.Tapinarof Selectivity and Mechanism of Action for PP Treatment

EP: 14.Long-Term Efficacy and Safety Data on PP Treatments

EP: 15.Identifying the Remittive Effect in PP Patients

EP: 16.Positioning Aryl Hydrocarbon Receptor Agonists in PP Treatment Regimens

Now Viewing

EP: 17.Key Takeaways for the Management of PP

EP: 18.Considering Plaque Psoriasis Comorbidities in Treatment Plans

Transcript

Lauren Miller, MPAS, PA-C: If you had to come up with a few take-home messages for viewers when it comes to treating patients—we’ll talk specifically about topical therapies—what are some of the high points of our discussion for PAs [physician assistants] and NPs [nurse practitioners]?

TJ Chao, MPAS, PA-C: The most important thing—I’ve learned this from treating patients with the newer products over the last year or so—is that you do need to take that extra step and educate patients that tapinarof may take a little longer. It’s not a steroid. If they’re used to using steroids and then they use tapinarof, they may think it’s not working because it’s not totally clear in 2 days. It’s important to educate the patient that this is going to take over a little longer than what they’re used to, but once you get to where you want to be, it’s going to pay off tremendously. You’ll be able to get that remittive effect and stop using the product over time. It’s a completely different way of thinking about topical steroids. It’s as if we have to change the patient’s perspective of how they view topical therapy.

Lauren Miller, MPAS, PA-C: We’re changing the paradigm. For topical therapy in general, we want to keep in mind what body parts we’re talking about and the severity of the disease. We’re advocates for our patients. Often we’re very busy. I’m sure you see a ton of patients every day, and it’s very easy to get in the habit of [giving something to] a patient because it’s easy: we know it, and the patients are familiar with it. But 1 of the take-home [messages] is be an advocate for them. Take the time to talk to them about all their options—the downsides, the pros—and listen to the patient. Ask them, “What is it you want to get out of this? What is it about your disease that bothers you the most?” That will help guide you into prescribing whatever the best therapeutic option is for them.

TJ Chao, MPAS, PA-C: I completely agree.

Lauren Miller, MPAS, PA-C: Thank you for joining us for this Dermatology Times® DermView. I hope you found this to be useful and informative. We’ll see you next time.

Transcript edited for clarity.